Rosuvastatin calcium in acute coronary syndromes.

@article{Aggarwal2013RosuvastatinCI,
  title={Rosuvastatin calcium in acute coronary syndromes.},
  author={Rajesh K. Aggarwal and Refai Showkathali},
  journal={Expert opinion on pharmacotherapy},
  year={2013},
  volume={14 9},
  pages={
          1215-27
        }
}
INTRODUCTION Low-density lipoprotein cholesterol (LDL-C) reduction using 3-hydroxy-3-methyl glutaryl coenzyme A (HMGCoA) reductase inhibitors (statins) has a proven survival benefit in patients presenting with acute coronary syndromes (ACS). Patients presenting with ACS remain at significant risk of subsequent cardiovascular death and non-fatal myocardial infarction despite high compliance with current guideline indicated secondary prevention therapies. There remains, therefore, a need to… CONTINUE READING
2
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 81 REFERENCES

A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events – Reduction of Cholesterol to Key European Targets Trial

  • European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology
  • 2009
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL